William Blair Reaffirms Outperform Rating for Encompass Health (NYSE:EHC)

Encompass Health (NYSE:EHC)‘s stock had its “outperform” rating reaffirmed by research analysts at William Blair in a note issued to investors on Friday,RTT News reports.

A number of other research firms have also weighed in on EHC. KeyCorp boosted their target price on Encompass Health from $115.00 to $117.00 and gave the company an “overweight” rating in a research note on Tuesday, October 29th. Truist Financial reiterated a “buy” rating and set a $116.00 target price (up previously from $108.00) on shares of Encompass Health in a report on Wednesday, October 30th. Royal Bank of Canada increased their target price on Encompass Health from $105.00 to $110.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Finally, Barclays increased their target price on Encompass Health from $109.00 to $116.00 and gave the company an “overweight” rating in a research note on Tuesday, October 29th. Nine research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $107.11.

Encompass Health Stock Performance

Encompass Health stock traded down $0.36 during mid-day trading on Friday, reaching $98.24. 183,290 shares of the company’s stock were exchanged, compared to its average volume of 623,650. The firm has a market capitalization of $9.90 billion, a PE ratio of 23.82, a P/E/G ratio of 1.18 and a beta of 0.90. The business’s fifty day simple moving average is $96.34 and its 200 day simple moving average is $95.10. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.88. Encompass Health has a one year low of $72.37 and a one year high of $104.55.

Encompass Health (NYSE:EHC) last announced its quarterly earnings results on Thursday, February 6th. The company reported $1.17 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.12. Encompass Health had a return on equity of 17.60% and a net margin of 8.10%. On average, sell-side analysts expect that Encompass Health will post 4.29 earnings per share for the current year.

Hedge Funds Weigh In On Encompass Health

Institutional investors and hedge funds have recently bought and sold shares of the company. Truist Financial Corp raised its position in shares of Encompass Health by 1.1% in the second quarter. Truist Financial Corp now owns 19,338 shares of the company’s stock worth $1,659,000 after acquiring an additional 205 shares during the period. Cetera Investment Advisers grew its stake in Encompass Health by 5.7% during the 2nd quarter. Cetera Investment Advisers now owns 12,353 shares of the company’s stock valued at $1,060,000 after acquiring an additional 664 shares in the last quarter. Sanctuary Advisors LLC purchased a new stake in shares of Encompass Health in the 2nd quarter valued at approximately $1,384,000. GAMMA Investing LLC grew its stake in shares of Encompass Health by 34.7% in the 3rd quarter. GAMMA Investing LLC now owns 1,595 shares of the company’s stock valued at $154,000 after buying an additional 411 shares during the period. Finally, CWM LLC grew its stake in shares of Encompass Health by 27.8% in the 3rd quarter. CWM LLC now owns 8,164 shares of the company’s stock valued at $789,000 after buying an additional 1,776 shares during the period. 97.25% of the stock is owned by hedge funds and other institutional investors.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.